Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Sam Martin plans to retire effective on or about March 31, 2027.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Sam Martin plans to retire effective on or about March 31, 2027
- Martin has served as CFO since July 2017, providing extended leadership continuity
- Company search underway for successor, creating near-term executive transition risk
- Martin expected to remain CFO until March 31, 2027 or successor appointment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.